胃癌患者术前新辅助化疗的效果观察被引量：1

下载PDF

导出

摘要目的探讨胃癌患者术前行新辅助化疗(FOLFOX方案,甲酰四氢叶酸+5-氟尿嘧啶+奥沙利铂)的临床效果。方法选取2015年1月至2017年12月本院收治的124例进展期胃癌患者作为研究对象,根据随机、对照、前瞻性原则将124例患者分到观察组(n=62例)与对照组(n=62例),两组患者均行胃癌D2根治术治疗,观察组患者在手术前加以新辅助化疗治疗。对比分析两组患者的D2淋巴结清扫率、R0切除率及化疗疗效。结果观察组的D2淋巴结清扫率、R0切除率、总有效率均明显高于对照组,均有P<0.05。结论在胃癌患者术前行新辅助化疗治疗,可有效提高D2淋巴结清扫率、R0切除率及临床疗效。

作者陈大欣

机构地区丹东市第一医院普外一科

出处《中国医药指南》 2019年第36期130-130,共1页 Guide of China Medicine

关键词新辅助化疗胃肿瘤淋巴结清扫

分类号 R7352 [医药卫生—肿瘤]

引文网络
相关文献

参考文献3

1王先国,陈景华,李宇,张山燕,周远.卡培他滨联合奥沙利铂术前新辅助化疗治疗中晚期胃癌的临床观察[J].中国肿瘤临床与康复,2015,22(1):43-45. 被引量：20
2高皓阳,王静.胃癌患者术前新辅助化疗应用观察[J].山东医药,2015,55(11):86-88. 被引量：8
3吴春波.术前新辅助化疗治疗进展期胃癌的临床疗效分析[J].临床合理用药杂志,2017,10(16):81-82. 被引量：4

二级参考文献25

1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量：1506
2Zhang ZD,Kong Y,Yang W,et al.Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer[J].World J Surg Oncol,2014,12:115-116. 被引量：1
3Yu Z,Yu JK,Fang XF,et al.Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform[J].Hepatogastroenterology,2013,60:1800-1804. 被引量：1
4Lu Y,Liu Z,Zhang J,et al.S-1 plus oxaliplatin vs S-1 as firstline treatment in patients with previously untreated advanced gastric cancer:a randomized phase II study[J].J Chemother,2014,26:159-164. 被引量：1
5Wang M,Wu M,Wang W,et al.Docetexal plus S-1 versus oxaliplatin plus S-1 for first-line treatment of patients with advanced gastric cancer:a retrospective study[J].Oncol Res Treat,2014,37:24-28. 被引量：1
6Gaspar M J,Arribas I,Coca M C,et al.Prognostic value of carcinoembryonic antigen, CA19-9 and CA72-4 in gastric carcinoma. Tumour Biology . 2001 被引量：2
7Cunningham David,Allum William H,Stenning Sally P,Thompson Jeremy N,Van de Velde Cornelis J H,Nicolson Marianne,Scarffe J Howard,Lofts Fiona J,Falk Stephen J,Iveson Timothy J,Smith David B,Langley Ruth E,Verma Monica,Weeden Simon,Chua Yu Jo.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[].The New England Quarterly.2006 被引量：9
8Jian Guo Zhao,Feng Qiu,Jian Ping Xiong,Ling Zhang,Xiao Jun Xiang,Feng Yu,Jun Yan,Zhen Yu Zhan,Miao Feng.A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer[J]. Anti-Cancer Drugs . 2009 (4) 被引量：1
9Quoc T. Ho,Calvin J. Kuo.Vascular endothelial growth factor: Biology and therapeutic applications[J]. International Journal of Biochemistry and Cell Biology . 2007 (7) 被引量：3
10Theodoros Foukakis,Lars Lundell,Michael Gubanski,Pehr A. Lind.Advances in the treatment of patients with gastric adenocarcinoma[J]. Acta Oncologica . 2007 (3) 被引量：1